Effects of monoamine oxidase inhibitors on the diethyldithiocarbamate-induced enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in C57BL/6 mice

Journal of Neural Transmission

Volumn 110, Issue 8, 2003, Pages 859-869

  Takahata, K ^a   Shimazu, S ^a   Yoneda, F ^a   Ogawa, M ^b   Iida, Y ^b   Saji, H ^b  

^a Fujimoto Pharmaceutical Corporation   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine (MPTP); Clorgyline; Diethyldithiocarbamate (DDC); Parkinson's disease; Selegiline

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID ISOPROPYL ESTER; CLORGYLINE; DIETHYLDITHIOCARBAMIC ACID; DOPAMINE; IODINE 125; MONOAMINE OXIDASE INHIBITOR; SELEGILINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRADYKINESIA; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG ANTAGONISM; DRUG POTENTIATION; MALE; MOUSE; MOUSE STRAIN; NERVE DEGENERATION; NERVE ENDING; NEUROTOXICITY; NONHUMAN; OLFACTORY NUCLEUS; PRIORITY JOURNAL; STRIATE CORTEX; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BODY WEIGHT; CELL DEATH; CLORGYLINE; DISEASE MODELS, ANIMAL; DITIOCARB; DOPAMINE; DOWN-REGULATION; DRUG SYNERGISM; MALE; MICE; MICE, INBRED C57BL; MONOAMINE OXIDASE INHIBITORS; NEOSTRIATUM; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; PRESYNAPTIC TERMINALS; SELEGILINE; SUBSTANTIA NIGRA;

EID: 0042405004     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-003-0003-0     Document Type: Article

References (34)

1. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J (1985) Increased life expectancy resulting from addition of L-deprenyl to madopar treatment in Parkinson's disease: a longterm study. J Neural Transm 64: 113-127
2. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 80: 4546-4550
3. Carrillo M-C, Kanai S, Nokubo M, Ivy GO, Sato Y, Kitani K (1992) (-)Deprenyl increases activities of superoxide dismutase and catalase in striatum but not in hippocampus: the sex and age-related differences in the optimal dose in the rat. Exp Neurol 116: 286-294
4. Chiba K, Trevor A, Castagnoli N (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120: 574-578
5. + inhibition of complex I. FEBS Lett 504: 50-52
6. Cohen G, Pasik P, Cohen B, Leist A, Mytilineou C, Yahr MD (1984) Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 106: 209-210
7. Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ (1979) Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1: 249-254
8. Elverfors A, Pileblad E, Lagerkvist S, Bergquist F, Jonason J, Nissbrandt H (1997) 3-Methoxytyramine formation following monoamine oxidase inhibition is a poor index of dendritic dopamine release in the substantia nigra. J Neurochem 69: 1684-1692
9. Fornai F, Carri MT, Ferri A, Paolucci E, Prisco S, Bernardi G, Rotilio G, Mercuri NB (2002) Resistance to striatal dopamine depletion induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice expressing human mutant Cu, Zn superoxide dismutase. Neurosci Lett 325: 124-128
10. Hallman H, Lange J, Olson L, Strömberg I, Jonsson G (1985) Neurochemical and histochemical characterization of neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse. J Neurochem 44: 117-127
11. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311: 467-469
12. Honkanen A, Chrapusta SJ, Karoum F, Korpi ER (1994) Alterations in dopamine metabolism by intraperitoneal ethanol in rats selected for high and low ethanol preference: a 3-methoxytyramine study. Alcohol 11: 323-328
13. Irwin I, Wu EY, DeLanney LE, Trevor A, Langston JW (1987) The effect of diethyldithiocarbamate on the biodisposition of MPTP: an explanation for enhanced neurotoxicity. Eur J Pharmacol 141: 209-217
14. Kopin IJ, Markey SP (1988) MPTP toxicity: implications for research in Parkinson's disease. Annu Rev Neurosci 11: 81-96
15. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979-980
16. Malorni W, Giammarioli AM, Matarrese P, Pietrangeli P, Agostinelli E, Ciaccio A, Grassilli E, Mondovi B (1998) Protection against apoptosis by monoamine oxidase A inhibitors. FEBS Lett 426: 155-159
17. Maragos WF, Tillman PA, Chesnut MD, Jakel RJ (1999) Clorgyline and deprenyl attenuate striatal malonate and 3-nitropropionic acid lesions. Brain Res 834: 168-172
18. Miller DB, Reinhard JF, Daniels AJ, O'Callaghan JP (1991) Diethyldithiocarbamate potentiates the neurotoxicity of in vivo 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and of in vitro 1-methyl-4-phenylpyridinium. J Neurochem 57: 541-549
19. Mytilineou C, Leonardi EK, Radcliffe P, Heinonen EH, Han S-K, Werner P, Cohen G, Olanow CW (1998) Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion. J Pharmcol Exp Ther 284: 700-706
20. Nyitrai G, Kekesi KA, Dobolyi K, Pungor K, Juhasz G (1997) Single low dose of MPTP decreases extracellular levels of noradrenaline and monoamine metabolites in the ventrobasal thalamus of the rats. Neurobiology 5: 249-261
21. Ogawa N, Hirose Y, Ohara S, Ono T, Watanabe Y (1985) A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmacol 50: 435-441
22. Ogawa N, Mizukawa K, Hirose Y, Kajita S, Ohara S, Watanabe Y (1987) MPTP-induced parkinsonian model in mice: biochemistry, pharmacology and behavior. Eur Neurol 26: 16-23
23. Paterson IA, Juorio AV, Berry MD, Zhu MY (1991) Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum. J Pharmacol Exp Ther 258: 1019-1026
24. Saji H, Iida Y, Kawashima H, Ogawa M, Kitamura Y, Mukai T, Shimazu S, Yoneda F (2003) In vivo imaging of brain dopaminergic neurotransmission system in small animals with high-resolution single photon emission computed tomography. Anal Sci 19: 67-71
25. Shimazu S, Katsuki H, Akaike A (1999) Deprenyl rescues dopaminergic neurons in organotypic slice cultures of neonatal rat mesencephalon from N-methyl-D-aspartate toxicity. Eur J Pharmacol 377: 29-34
26. Shimazu S, Takahata K, Tamashiro A, Yoneda F, Iida Y, Saji H (2003) Recovery of the motor function and dopaminergic parameters in a mouse model of Parkinson's disease induced by co-administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate. J Neural Transm 110 (in press)
27. Suzuki T, Akaike N, Ueno K, Tanaka Y, Himori N (1995) MAO inhibitors, clorgyline and lazabemide, prevent hydroxyl radical generation caused by brain ischemia/reperfusion in mice. Pharmacology 50: 357-362
28. Szczypka MS, Rainey MA, Kim DS, Alaynick WA, Marck BT, Matsumoto AM, Palmiter RD (1999) Feeding behavior in dopamine-deficient mice. Proc Natl Acad Sci USA 96: 12138-12143
29. Takahata K, Katsuki H, Kobayashi Y, Muraoka S, Yoneda F, Kume T, Kashii S, Honda Y, Akaike A (2003) Protective effects of selegiline and desmethylselegiline against N-methyl-D-aspartate-induced rat retinal damage. Eur J Pharmacol 458: 81-89
30. Tatton WG (1999) Apoptotic mechanisms in neurodegeneration: possible relevance to glaucoma. Eur J Ophthalmol 9: S22-S29
31. Tella SR, Ladenheim B, Cadet JL (1997) Differential regulation of dopamine transporter after chronic self-administration of bupropion and nomifensine. J Pharmacol Exp Ther 281: 508-513
32. The Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 321: 1364-1371
33. Vaglini F, Fascetti E Fomai F, Maggio R, Corsini GU (1994) (+)MK-801 prevents the DDC-induced enhancement of MPTP toxicity in mice. Brain Res 668: 194-203
34. Walters TL, Irwin I, Delfani K, Langston JW, Janson AM (1999) Diethyldithiocarbamate causes nigral cell loss and dopamine depletion with nontoxic doses of MPTP. Exp Neurol 156: 62-70